SG10201401515YA - PCSK9 vaccine - Google Patents

PCSK9 vaccine

Info

Publication number
SG10201401515YA
SG10201401515YA SG10201401515YA SG10201401515YA SG10201401515YA SG 10201401515Y A SG10201401515Y A SG 10201401515YA SG 10201401515Y A SG10201401515Y A SG 10201401515YA SG 10201401515Y A SG10201401515Y A SG 10201401515YA SG 10201401515Y A SG10201401515Y A SG 10201401515YA
Authority
SG
Singapore
Prior art keywords
pcsk9 vaccine
pcsk9
vaccine
Prior art date
Application number
SG10201401515YA
Inventor
Brian Robert Champion
Jr Leaonard Gabriel Contillo
Michael Dale Eisenbraun
James Downey Fraser
Julie Jia Li Hawkins
James Richard Merson
Brian Gregory Pierce
Xiayang Qiu
Jakir Hussain Ullah
David Michael Wyatt
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of SG10201401515YA publication Critical patent/SG10201401515YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/005Trypanosoma antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21061Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
SG10201401515YA 2009-09-03 2010-08-23 PCSK9 vaccine SG10201401515YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23954109P 2009-09-03 2009-09-03

Publications (1)

Publication Number Publication Date
SG10201401515YA true SG10201401515YA (en) 2014-08-28

Family

ID=43413463

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201401515YA SG10201401515YA (en) 2009-09-03 2010-08-23 PCSK9 vaccine
SG10201401516XA SG10201401516XA (en) 2009-09-03 2010-08-23 Pcsk9 vaccine
SG2012010740A SG178447A1 (en) 2009-09-03 2010-08-23 Pcsk9 vaccine

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201401516XA SG10201401516XA (en) 2009-09-03 2010-08-23 Pcsk9 vaccine
SG2012010740A SG178447A1 (en) 2009-09-03 2010-08-23 Pcsk9 vaccine

Country Status (30)

Country Link
US (4) US8889144B2 (en)
EP (3) EP2865752A1 (en)
JP (5) JP2013503623A (en)
KR (3) KR101660578B1 (en)
CN (3) CN104548089B (en)
AR (2) AR078247A1 (en)
AU (1) AU2010290931B2 (en)
BR (1) BR112012004807A2 (en)
CA (2) CA2771770A1 (en)
CO (1) CO6501190A2 (en)
DK (1) DK2473605T3 (en)
ES (1) ES2670576T3 (en)
HK (3) HK1174056A1 (en)
HU (1) HUE037416T2 (en)
IL (2) IL218229A (en)
MX (1) MX2012002639A (en)
MY (1) MY163512A (en)
NO (1) NO2473605T3 (en)
NZ (3) NZ620441A (en)
PE (3) PE20161560A1 (en)
PH (2) PH12016500004A1 (en)
PL (1) PL2473605T3 (en)
PT (1) PT2473605T (en)
RU (2) RU2538162C2 (en)
SA (3) SA110310687B1 (en)
SG (3) SG10201401515YA (en)
SI (1) SI2473605T1 (en)
TR (1) TR201808222T4 (en)
TW (1) TWI400085B (en)
WO (1) WO2011027257A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266582B (en) 2008-08-29 2021-09-10 口腔健康澳洲私人有限公司 Prevention, treatment and diagnosis of Porphyromonas gingivalis infection
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
PE20110998A1 (en) 2008-12-09 2012-02-10 Coley Pharm Group Inc IMMUNOSTIMULATORY OLIGONUCLEOTIDES
GB201005005D0 (en) * 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
US20140004142A1 (en) * 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EP2532359A1 (en) 2011-06-10 2012-12-12 Affiris AG CETP fragments
EP2570135B1 (en) 2011-09-13 2016-01-27 Affiris AG PCSK9 Vaccine
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP2908854A2 (en) * 2012-10-17 2015-08-26 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
WO2014074509A1 (en) * 2012-11-07 2014-05-15 Vacplanta Limted Production of an immunogen using a plant virus
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
TWI641382B (en) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 A method of virus inactivation in composition comprising factor vii
CN104043120B (en) * 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 Hepatitis b vaccine
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
US10004791B2 (en) * 2014-02-28 2018-06-26 Affiris Ag Peptide vaccines against PCSK9
CN104558199B (en) * 2014-09-05 2018-07-06 成都康弘生物科技有限公司 A kind of fusion protein preparation for treating hypercholesterolemia and application thereof
RU2736642C2 (en) * 2015-07-20 2020-11-19 Зоэтис Сервисиз Ллс Liposomal adjuvant compositions
EP3365006A1 (en) 2015-10-19 2018-08-29 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
WO2017076873A1 (en) * 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
US10980876B2 (en) * 2016-03-25 2021-04-20 Osaka University Conjugate vaccine targeting a disease-causing biological protein
CA3026823A1 (en) * 2016-06-24 2017-12-28 F. Hoffmann-La Roche Ag Compositions and methods for treating cardiovascular disease
CN106822881A (en) * 2016-12-09 2017-06-13 四川大学 A kind of hyperlipoproteinemia vaccine for PCSK9
CA3058567A1 (en) * 2017-04-13 2018-10-18 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
CN107488215A (en) * 2017-07-19 2017-12-19 邱志华 The immunogenicity peptide fragment of people's proprotein convertases subtilisin 9 and its carrier bacterin
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
WO2021154947A1 (en) * 2020-01-28 2021-08-05 Ubi Ip Holdings Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
WO2022147373A1 (en) * 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN117327159A (en) * 2023-07-31 2024-01-02 杭州纽龙生物科技有限公司 Alkali-resistant mutation method for protein A

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1980000727A1 (en) 1978-09-29 1980-04-17 Secretary Energy Brit Improvements in and relating to electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
AU548727B2 (en) 1981-03-12 1986-01-02 Gruppo Lepetit S.P.A. Beta-lactam acetic acid derivatives
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (en) 1981-10-23 1992-06-04 Molecular Biosystems Inc OLIGONUCLEOTIDES MEDICINE AND THEIR PRODUCTION METHOD.
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (en) 1983-12-26 1985-07-20 Eisai Co Ltd Remedy and preventive for hyperlipemia
DE3423166A1 (en) 1984-06-22 1986-01-02 Epis S.A., Zug ALPHA, OMEGA DICARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
ES2055785T3 (en) 1989-01-17 1994-09-01 Eniricerche Spa SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH04506662A (en) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー Cytokinin and hormone carriers for conjugate vaccines
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
JP2999579B2 (en) 1990-07-18 2000-01-17 武田薬品工業株式会社 DNA and its uses
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
DE4202394A1 (en) 1991-04-04 1992-10-08 Teves Gmbh Alfred SWIMMING CALIPER PART COVER DISC BRAKE WITH A BRAKE CASE MADE OF LIGHT METAL
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
ES2143716T3 (en) 1992-06-25 2000-05-16 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1185811A (en) 1995-03-31 1998-06-24 H·沃尔夫 Antigen presentation system on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (en) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Process for the preparation of nucleic acid constructs
PT1003850E (en) 1997-06-06 2009-08-13 Dynavax Tech Corp Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
DE69815692T2 (en) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. OIL IN WATER EMULSIONS WITH SAPONINES
ID26669A (en) 1998-02-12 2001-01-25 Immune Complex Corp INTI HEPATITIS B PROTEINS MODIFIED BY STRATEGY AND ITS DECREASES
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002511423A (en) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE59806475D1 (en) 1998-09-18 2003-01-09 Pentapharm Ag Basel Urokinase INHIBITORS
WO2000021478A1 (en) 1998-09-28 2000-04-20 Hans Balle Aps Lift, preferably for seats on wheelchairs
US6203837B1 (en) 1998-10-06 2001-03-20 Xcafe' Llc Coffee system
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
AU770802B2 (en) 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
WO2000026385A1 (en) 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
CN100534529C (en) 1998-11-30 2009-09-02 希托斯生物技术股份公司 Ordered molecular presentation of antigens, method of preparation and use
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
TR200200633T2 (en) 1998-12-23 2002-06-21 Shire Biochem Inc. New streptococcus antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
BR0009520A (en) 1999-04-01 2002-06-11 Esperion Therapeutics Inc Compound, method to synthesize the same, composition, methods for treatment or prevention, in a patient, of cardiovascular disease, dyslipidemia, dyslipoproteinemia, glucose metabolism disorder, alzheimer's disease, syndrome x or metabolic syndrome, septicemia, thrombotic disorder, disorder associated with peroxisome proliferator-activated receptor, obesity, pancreatitis, hypertension, kidney disease, cancer, inflammation, impotence, to reduce the fat content of beef cattle, and to reduce the cholesterol content of poultry eggs
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
PT1187629E (en) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE
NO309798B1 (en) * 1999-04-30 2001-04-02 Targovax As Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition
CO5200837A1 (en) 1999-09-24 2002-09-27 Smithkline Beecham Corp VACCINES
PL355232A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
EP1220684B2 (en) 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
EP1268530B1 (en) 2000-04-07 2006-08-16 University Of Leeds Hepatitis b core antigen fusion proteins
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
NZ553554A (en) 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
ES2260235T3 (en) 2000-06-22 2006-11-01 Ucb Pharma Limited MODIFICATION OF THE "CORE" ANTIGEN OF HEPATITIS B.
EP1304947A1 (en) 2000-07-15 2003-05-02 Lighthouse Display International Limited Shelf edge display fittings
GB0121171D0 (en) * 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (en) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
JP4671389B2 (en) 2001-10-05 2011-04-13 サイトス バイオテクノロジー アーゲー Angiotensin peptide-carrier complex and use thereof
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
AU2003213168A1 (en) 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
MXPA05000277A (en) 2002-07-17 2005-03-31 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the ap205 coat protein.
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
ATE546156T1 (en) 2002-12-10 2012-03-15 Sanofi Pasteur Biologics Co STABILIZED IMMUNOGENIC CHIMERIC HBC PARTICLES
DE602004010376T2 (en) 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. PROCESS FOR CLEANING BACTERIAL CYTOLYSIN
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JP2008506683A (en) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ, リミテッド Methods and compositions for inducing innate immune responses
NZ553244A (en) 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2553284T5 (en) 2006-02-15 2021-08-31 Rechtsanwalt Thomas Beck Compositions and Procedures for Oligonucleotide Formulations
CA2652247C (en) * 2006-05-08 2015-11-17 Adaerata, Limited Partnership Chimeric pcsk9 proteins, cells comprising same, and assays using same
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
US8263353B2 (en) * 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
AR066042A1 (en) * 2007-04-13 2009-07-22 Novartis Ag MOLECULES AND METHODS TO MODULATE PROTEIN CONVERTASA-SUBTILISIN / QUEXIN TYPE 9 (PCSK9)
KR20100045445A (en) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
JOP20080381B1 (en) * 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
US8598320B2 (en) * 2007-10-26 2013-12-03 Merck Sharp & Dohme Corp. Anti-PCSK9 and methods for treating lipid and cholesterol disorders
CA2710141A1 (en) * 2007-12-20 2009-07-02 Cytos Biotechnology Ag Ngf conjugates and uses thereof
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) * 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
TWI516501B (en) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
AT507604A1 (en) 2008-11-19 2010-06-15 Affiris Forschungs & Entwicklungs Gmbh TREATMENT OF ATHEROSCLEROSIS
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
WO2017221077A2 (en) 2016-06-23 2017-12-28 Steam Cc Ltd. Method and apparatus for printing on a drink
US10114918B2 (en) 2016-01-27 2018-10-30 Arm Limited Physical placement control for an integrated circuit based on state bounds file

Also Published As

Publication number Publication date
JP5859150B2 (en) 2016-02-10
BR112012004807A2 (en) 2017-04-11
PE20161551A1 (en) 2017-01-18
RU2014143531A (en) 2016-05-20
JP2018039821A (en) 2018-03-15
EP2473605B1 (en) 2018-04-11
PE20121544A1 (en) 2012-12-02
AR078247A1 (en) 2011-10-26
IL218229A (en) 2017-10-31
SG178447A1 (en) 2012-03-29
US8889144B2 (en) 2014-11-18
EP2473605A2 (en) 2012-07-11
KR20120089451A (en) 2012-08-10
HK1209619A1 (en) 2016-04-08
IL254600A0 (en) 2017-11-30
HUE037416T2 (en) 2018-08-28
RU2014143531A3 (en) 2018-06-22
JP2013503623A (en) 2013-02-04
AR107020A2 (en) 2018-03-14
RU2538162C2 (en) 2015-01-10
KR101660577B1 (en) 2016-09-27
TW201113035A (en) 2011-04-16
CN104587462B (en) 2017-09-26
CO6501190A2 (en) 2012-08-15
JP2017039748A (en) 2017-02-23
KR20140004263A (en) 2014-01-10
DK2473605T3 (en) 2018-05-28
CN102612558B (en) 2015-02-11
AU2010290931B2 (en) 2014-02-06
AU2010290931A1 (en) 2012-03-29
SI2473605T1 (en) 2018-06-29
US20170100467A1 (en) 2017-04-13
US9987341B2 (en) 2018-06-05
PE20161560A1 (en) 2017-01-11
CA2771770A1 (en) 2011-03-10
SA114350178B1 (en) 2017-03-05
ES2670576T3 (en) 2018-05-31
PH12016500004A1 (en) 2016-12-05
JP2015131814A (en) 2015-07-23
TR201808222T4 (en) 2018-07-23
SA114350179B1 (en) 2016-03-01
KR20140007500A (en) 2014-01-17
CN104587462A (en) 2015-05-06
PT2473605T (en) 2018-05-28
NZ599059A (en) 2014-05-30
HK1174056A1 (en) 2013-05-31
US9481875B2 (en) 2016-11-01
PH12016500040A1 (en) 2016-12-05
KR101660578B1 (en) 2016-09-27
SA110310687B1 (en) 2014-10-16
CN104548089A (en) 2015-04-29
RU2012107657A (en) 2013-10-10
US20180318407A1 (en) 2018-11-08
TWI400085B (en) 2013-07-01
NZ710626A (en) 2017-03-31
NZ620441A (en) 2015-08-28
SG10201401516XA (en) 2014-10-30
MY163512A (en) 2017-09-15
PL2473605T3 (en) 2018-08-31
US20150098957A1 (en) 2015-04-09
US20110052621A1 (en) 2011-03-03
WO2011027257A3 (en) 2011-06-30
IL218229A0 (en) 2012-04-30
CN102612558A (en) 2012-07-25
KR101512053B1 (en) 2015-04-28
NO2473605T3 (en) 2018-09-08
HK1208346A1 (en) 2016-03-04
MX2012002639A (en) 2012-03-14
WO2011027257A2 (en) 2011-03-10
CA2846746A1 (en) 2011-03-10
EP3358008A1 (en) 2018-08-08
CN104548089B (en) 2017-09-26
JP2016106089A (en) 2016-06-16
EP2865752A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
IL254600A0 (en) Pcsk9 vaccine
IL217008A0 (en) Vaccine
GB0905570D0 (en) Combined vaccines
IL211233A0 (en) Vaccine
HRP20151124T1 (en) Vaccine
EP2408473A4 (en) Vaccination methods
GB0822001D0 (en) Vaccine
GB201006165D0 (en) Vaccine
GB0810710D0 (en) Vaccine
IL208652A0 (en) Vaccine
GB0816284D0 (en) Vaccine
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
GB0816447D0 (en) Vaccine
GB201000522D0 (en) Vaccine
IL217194A0 (en) Vaccine
GB0914545D0 (en) Vaccine
ZA201107971B (en) Combined measles-malaria vaccine
GB0909146D0 (en) Vaccines
GB0909147D0 (en) Vaccines
GB0909145D0 (en) Vaccines
GB0909144D0 (en) Vaccines
GB0810215D0 (en) Vaccine
GB0810914D0 (en) Vaccine
GB0809781D0 (en) Vaccine